GlassScriptPhysician profile
Joan A Chandra
NPI 1265886394
$10,481.54
in general payments reported to CMS, 2019-2025
30 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,274 · 2023: $3,574 · 2024: $3,966 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,078 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,077.66 |
| Education | $129.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,233.28 | 2022-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $1,523.98 | 2022-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $954.54 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $840.46 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Intercept Pharmaceuticals, INC. | $678.68 | 2022-2025 | Ocaliva |
| Lilly USA, LLC | $544.56 | 2023-2025 | Omvoh, Zepbound |
| Pfizer INC. | $519.89 | 2022-2025 | |
| Celgene Corporation | $421.14 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $369.36 | 2022-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $332.31 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $287.02 | 2022-2024 | Dificid, Zinplava |
| Genzyme Corporation | $211.84 | 2022-2024 | |
| Celltrion USA INC. | $210.56 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Ferring Pharmaceuticals INC. | $192.89 | 2022-2023 | Rebyota, Clenpiq |
| Ardelyx, INC. | $174.17 | 2023-2025 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $147.33 | 2023-2024 | Idacio |
| Janssen Scientific Affairs, LLC | $138.46 | 2023 | Stelara |
| Nestle Healthcare Nutrition INC. | $125.33 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $107.58 | 2023-2025 | Voquezna |
| Daiichi Sankyo INC. | $96.16 | 2024 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $85.37 | 2023 | Zeposia |
| Aimmune Therapeutics, INC. | $59.67 | 2024-2025 | Vowst |
| Madrigal Pharmaceuticals | $56.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $46.98 | 2023 | Avsola, Amjevita |
| Ipsen Biopharmaceuticals, INC | $26.71 | 2024 | Iqirvo |
| Capsovision, INC. | $25.98 | 2024 | Capsocam Plus |
| Stryker Corporation | $23.67 | 2024 | Neptune |
| Sandoz INC. | $19.82 | 2023 | Hyrimoz |
| Ucb, INC. | $15.54 | 2024 | Cimzia |
| Organon LLC | $11.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.